Verus Capital Partners LLC Sells 229 Shares of Eli Lilly and Company (NYSE:LLY)

Verus Capital Partners LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 15.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,274 shares of the company’s stock after selling 229 shares during the quarter. Verus Capital Partners LLC’s holdings in Eli Lilly and Company were worth $684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the third quarter worth about $27,000. Retirement Group LLC raised its position in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the last quarter. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company during the third quarter worth about $35,000. Cornerstone Planning Group LLC bought a new stake in Eli Lilly and Company in the second quarter worth approximately $33,000. Finally, RVW Wealth LLC bought a new stake in Eli Lilly and Company in the third quarter worth approximately $46,000. 81.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LLY. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Wednesday, November 8th. Truist Financial reiterated a “buy” rating and issued a $650.00 target price on shares of Eli Lilly and Company in a report on Wednesday, November 29th. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $615.00 to $650.00 and gave the company an “overweight” rating in a report on Monday, October 9th. Morgan Stanley boosted their price objective on Eli Lilly and Company from $727.00 to $822.00 and gave the company an “overweight” rating in a report on Tuesday, December 19th. Finally, TheStreet downgraded Eli Lilly and Company from a “b” rating to a “c+” rating in a report on Monday, December 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $583.24.

Get Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Stock Down 0.9 %

LLY stock opened at $628.57 on Thursday. The stock’s fifty day simple moving average is $596.55 and its two-hundred day simple moving average is $556.04. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. Eli Lilly and Company has a 1-year low of $309.20 and a 1-year high of $647.73. The stock has a market cap of $596.71 billion, a P/E ratio of 113.87, a P/E/G ratio of 2.04 and a beta of 0.31.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.18. Eli Lilly and Company had a return on equity of 48.12% and a net margin of 15.55%. The business had revenue of $9.50 billion for the quarter, compared to analysts’ expectations of $8.88 billion. Analysts expect that Eli Lilly and Company will post 6.54 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 4th. Shareholders of record on Thursday, February 15th will be given a $1.30 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $5.20 annualized dividend and a yield of 0.83%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s payout ratio is currently 81.88%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 670 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $571.10, for a total value of $382,637.00. Following the sale, the chief accounting officer now directly owns 4,708 shares in the company, valued at $2,688,738.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the sale, the insider now directly owns 99,719,884 shares in the company, valued at approximately $63,004,019,910.04. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 670 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $571.10, for a total value of $382,637.00. Following the sale, the chief accounting officer now directly owns 4,708 shares in the company, valued at approximately $2,688,738.80. The disclosure for this sale can be found here. Insiders have sold a total of 63,120 shares of company stock worth $39,862,068 over the last ninety days. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.